H-1 PV EXPRESSING RNAI EFFECTORS TARGETING CDK9

The present invention relates to innovative protoparvoviruses (PV) expressing RNAi effectors, preferably shRNAs, against the CDK9 gene which display improved anticancer activity. These new viruses are based on the ”H-1PVsilencer platform that consists of a protoparvovirus H-1PV featuring an in-frame...

Full description

Saved in:
Bibliographic Details
Main Authors MARCHINI, Antonio, Nieto, Karen, LEUCHS, Barbara, Li-Weber, Min, Krammer, Peter, De-Oliveira, Anna-Paula, ROMMELAERE, Jean, Li, Junwei
Format Patent
LanguageEnglish
French
German
Published 30.05.2018
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to innovative protoparvoviruses (PV) expressing RNAi effectors, preferably shRNAs, against the CDK9 gene which display improved anticancer activity. These new viruses are based on the ”H-1PVsilencer platform that consists of a protoparvovirus H-1PV featuring an in-frame deletion within the NS region (”H-1PV) and harbouring a shRNA expression cassette in which the expression of the shRNA is controlled by the H1 Polymerase III promoter. In this invention the inventors aimed to use the ”H-1PVsilencer to silence the CDK9 gene whose activity is often dysregulated in cancer cells and known to contribute to tumorigenesis. The present invention also provides cells or organisms comprising said parvovirus.
Bibliography:Application Number: EP20160200978